India · Delayed Price · Currency is INR Orchid Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw a 5% YoY sales decline and margin compression due to global antibiotic market stress and lower regulated market sales. Cost optimization and R&D investments continue, while new launches and the 7-ACA project are expected to drive future growth.
-
Q2 FY26 saw a 13% YoY sales decline but sequential improvement, with gross margin compression due to weak pricing and inventory liquidation. Strategic acquisition of emmetazobactam rights positions for future growth, while the antibiotics market remains under pressure.
-
Q1 FY26 saw a 29% sales decline due to a global antibiotics slowdown, but gross margins were preserved at 42%. The company acquired global rights to Enmetazobactam, expects no debt for the deal, and is focused on disciplined execution and margin protection amid ongoing market contraction.
Fiscal Year 2025
-
Q4 and FY2024 saw double-digit sales and EBITDA growth, but ongoing pricing pressure and project delays are expected to mute FY2026 performance. The AMS division is building scale, Enmetazobactam is outperforming in India, and the Dhanuka merger is set to strengthen the business.
-
Q3 FY25 saw 15% YoY revenue growth and 26% PAT increase, with strong volume gains offset by price corrections in key products. Strategic investments in AMS and 7-ACA continue, while royalty income from Europe is ramping up. Gross margins remain stable at 40% ±2%.
-
Q2 FY25 sales reached INR 222.7 crores, with H1 sales up 22% year-over-year and EBITDA rising to INR 78.6 crores. Orblicef launched in India, Enmetazobactam sales began in the EU, and capacity expansion projects are on track. Management remains optimistic about future growth.
-
Q1 FY25 saw 34% revenue and 71% EBITDA growth, driven by strong capacity utilization and cost control. New product launches, major CapEx projects, and a Cipla partnership position the company for sustained growth, with full-year revenue expected to rise 20–25%.